Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | RAMP3 | O60896 | 8/20 | 0.40 |
| ▸ | CALCR | P30988 | 8/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.38 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30313493 | 0.98 | REN (0.40) | RENRAMP3CALCRMMP1MMP3 | |
| SCHEMBL30313548 | 0.94 | MMP1 (0.42) | RENRAMP3CALCRMMP1MMP3 | |
| SCHEMBL30313512 | 0.92 | RAMP3 (0.38) | RENRAMP3CALCRMMP1MMP3 | |
| SCHEMBL30313491 | 0.91 | MMP1 (0.43) | RENRAMP3CALCRMMP1MMP3 | |
| SCHEMBL30313483 | 0.91 | MMP1 (0.44) | RENMMP1MMP3APLNR | |
| SCHEMBL30313541 | 0.86 | MDM2 (0.44) | — | |
| SCHEMBL31297104 | 0.85 | REN (0.46) | RENAPLNR | |
| SCHEMBL30313550 | 0.85 | RAMP3 (0.40) | RENRAMP3CALCRMMP1MMP3 | |
| SCHEMBL31297108 | 0.83 | REN (0.46) | RENAPLNR | |
| SCHEMBL31655749 | 0.83 | F2 (0.40) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312648-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | YUYU PHARMA, INC. (KR) | 2023-10-05 | — | — | US | disclosed |
| US-11613558-B2 | Peptides and pharmaceutical compositions for treating eye diseases | YUYU PHARMA, INC. (KR) | 2023-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312648-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | VIP, IAPP, SCTR | REN 907/4885RAMP3 1391/4885CALCR 145/4885 |
| US-11613558-B2 | Peptides and pharmaceutical compositions for treating eye diseases | VIP, IAPP, SCTR | REN 907/4885RAMP3 1391/4885CALCR 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.